Literature DB >> 10612298

Hemoperfusion study with carbamazepine in vitro.

K Derzsiová1, M Mydlík, V Petríková.   

Abstract

Sorption efficacy of active charcoal, Amberlite XAD-2 and Amberlite XAD-4 in hemoperfusion with carbamazepine was investigated in vitro. Authors carried out 15 hemoperfusions with carbamazepine in a closed system using the above mentioned sorbents; The perfusion solution used was 3,000 ml of 0.9% NaCl. The carbamazepine concentration in the solution was 52.5+/-3.0 mg/L. In addition, two in vitro hemoperfusions with carbamazepine using Amberlite XAD-2 sorbent and 1.500 ml of human plasma as a perfusion solution, were also performed. The concentration of carbamazepine in plasma was 50.4+/-1.2 mg/L. Individual hemoperfusions lasted 5 hours. Zero values of carbamazepine were achieved after 120 min of Amberlite XAD-2 or Amberlite XAD-4 hemoperfusion in 0.9% NaCl and after 240 min of hemoperfusion in human plasma. The results gathered suggest that the most effective in vitro hemoperfusion with carbamazepine was obtained with Amberlite XAD-2 or Amberlite XAD-4 and the least effective was with active charcoal. The authors recommend the use of hemoperfusion with Amberlite XAD-2 or Amberlite XAD-4 for acute intoxications with carbamazepine in humans. In addition, authors successfully performed 5-hour hemoperfusion using Amberlite XAD-4 in vivo, in an 18-year-old girl, who suffered from acute carbamazepine intoxication after a suicidal attempt. This treatment led to the rapid survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10612298

Source DB:  PubMed          Journal:  Int J Artif Organs        ISSN: 0391-3988            Impact factor:   1.595


  1 in total

Review 1.  Extracorporeal treatment for carbamazepine poisoning: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Marc Ghannoum; Christopher Yates; Tais F Galvao; Kevin M Sowinski; Thi Hai Vân Vo; Andrew Coogan; Sophie Gosselin; Valery Lavergne; Thomas D Nolin; Robert S Hoffman
Journal:  Clin Toxicol (Phila)       Date:  2014-10-30       Impact factor: 4.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.